NIH Long COVID Initiative To Assess Pfizer's Antiviral Pill As Potential Treatment

 

• The National Institutes of Health's $1 billion RECOVER Initiative has decided to study Pfizer Inc's 
  PFE+0.03%+ Free Alerts
   antiviral drug Paxlovid as a potential treatment for long COVID.
• Long COVID involves more than 200 symptoms ranging from exhaustion and cognitive impairment to pain, fever, and heart palpitations that can last for months and even years following a COVID-19 infection.
• Estimates of long COVID prevalence range from 5 to 50% of people who have had a COVID-19 infection. It affects people with mild and severe COVID-19, including children.
• According to details posted on Clinicaltrials.gov, the randomized, placebo-controlled trial will test Pfizer's treatment or placebo in 1,700 adult volunteers.
• The Duke Clinical Research Institute is supervising the study, scheduled to start on January 1, 2023.
• Reuters reported that several patients reported improvements in their symptoms after taking Pfizer's antiviral treatment.
• Paxlovid is currently authorized for use in the first days of a COVID infection to prevent severe disease in high-risk patients.
• Some researchers found that naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.
• Naltrexone is a medication primarily used to manage alcohol or opioid use disorder.

https://www.benzinga.com/general/biotech/22/10/29457109/national-institutes-of-healths-long-covid-initiative-to-assess-pfizers-antiviral-pill-as-potentia